Conquering Diseases

Remdesivir For The Treatment Of Sars-Cov2 (Cov) Infection

Description

An investigational drug treatment for patients who have been hospitalized with the coronavirus COVID-19; University Campus

Overview

The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.

What we're hoping for

We are hoping that the experimental drug is safe for use and helps people hospitalized with the COVID-19 coronavirus recover.

Additional Information

ClinicalTrials.gov Identifier: NCT04323761

 Principal Investigator

Robert  Finberg, MD

University of Massachusetts Medical School

 Study Contact

Jaclyn  Longtine

508-856-5472

Jaclyn.Longtine@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989